Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bio-Rad Laboratories

250.08
0.0000
Post-market: 250.080.00000.00%16:04 EDT
Volume:13.00
Turnover:2.96K
Market Cap:6.81B
PE:-3.24
High:250.08
Open:250.08
Low:250.08
Close:250.08
Loading ...

Bio-Rad Laboratories Updates on Sartorius Investment

TIPRANKS
·
22 Feb

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
19 Feb

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks
·
17 Feb

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
15 Feb

Bio-Rad’s Cautious Optimism Amid Earnings Challenges

TIPRANKS
·
15 Feb

Bio-Rad Laboratories Shares Fall on 4Q Sales Miss, Cost-Cutting Plans

Dow Jones
·
15 Feb

RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating

MT Newswires Live
·
14 Feb

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

GuruFocus.com
·
14 Feb

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Zacks
·
14 Feb

Bio-Rad Laboratories' Q4 Adjusted Earnings, Revenue Fall

MT Newswires Live
·
14 Feb

Bio-Rad Laboratories Q4 2024 Adj EPS $2.90 Beats $2.86 Estimate, Sales $667.50M Miss $679.30M Estimate

Benzinga
·
14 Feb

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Business Wire
·
14 Feb

Oncocyte Prices $29 Million Stock Offerings

MT Newswires Live
·
11 Feb

Wells Fargo Sticks to Their Hold Rating for Bio-Rad Laboratories (BIO)

TIPRANKS
·
10 Feb

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Zacks
·
06 Feb

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Zacks
·
04 Feb

RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating

MT Newswires Live
·
04 Feb

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?

Insider Monkey
·
29 Jan

Press Release: Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Dow Jones
·
28 Jan

Strong week for Bio-Rad Laboratories (NYSE:BIO) shareholders doesn't alleviate pain of three-year loss

Simply Wall St.
·
28 Jan